These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 3899068

  • 1. The importance of high-tone audiometry in monitoring for ototoxicity.
    Tange RA, Dreschler WA, van der Hulst RJ.
    Arch Otorhinolaryngol; 1985; 242(1):77-81. PubMed ID: 3899068
    [Abstract] [Full Text] [Related]

  • 2. The role of high-frequency audiometry in early detection of ototoxicity.
    Dreschler WA, vd Hulst RJ, Tange RA, Urbanus NA.
    Audiology; 1985; 24(6):387-95. PubMed ID: 4084111
    [Abstract] [Full Text] [Related]

  • 3. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
    Reavis KM, Phillips DS, Fausti SA, Gordon JS, Helt WJ, Wilmington D, Bratt GW, Konrad-Martin D.
    Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
    [Abstract] [Full Text] [Related]

  • 4. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
    Stavroulaki P, Apostolopoulos N, Segas J, Tsakanikos M, Adamopoulos G.
    Int J Pediatr Otorhinolaryngol; 2001 May 31; 59(1):47-57. PubMed ID: 11376818
    [Abstract] [Full Text] [Related]

  • 5. High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives.
    van der Hulst RJ, Dreschler WA, Urbanus NA.
    Ann Otol Rhinol Laryngol; 1988 May 31; 97(2 Pt 1):133-7. PubMed ID: 3281541
    [Abstract] [Full Text] [Related]

  • 6. Development and validation of a cisplatin dose-ototoxicity model.
    Dille MF, Wilmington D, McMillan GP, Helt W, Fausti SA, Konrad-Martin D.
    J Am Acad Audiol; 2012 May 31; 23(7):510-21. PubMed ID: 22992258
    [Abstract] [Full Text] [Related]

  • 7. Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration.
    Waters GS, Ahmad M, Katsarkas A, Stanimir G, McKay J.
    Ear Hear; 1991 Apr 31; 12(2):91-102. PubMed ID: 2065844
    [Abstract] [Full Text] [Related]

  • 8. The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer.
    Caballero M, Mackers P, Reig O, Buxo E, Navarrete P, Blanch JL, Grau JJ.
    Oncology; 2017 Apr 31; 93(2):75-82. PubMed ID: 28511189
    [Abstract] [Full Text] [Related]

  • 9. [Hearing loss caused by high dose carboplatin therapy].
    Lautermann J, Adamczyk M, ten Cate WJ, Kloke O.
    Laryngorhinootologie; 1998 Feb 31; 77(2):82-4. PubMed ID: 9555700
    [Abstract] [Full Text] [Related]

  • 10. ABR obtained from time-efficient train stimuli for cisplatin ototoxicity monitoring.
    Dille MF, Ellingson RM, McMillan GP, Konrad-Martin D.
    J Am Acad Audiol; 2013 Oct 31; 24(9):769-81. PubMed ID: 24224985
    [Abstract] [Full Text] [Related]

  • 11. [The ototoxicity of cisplatin: a clinical study].
    Vantrappen G, Rector E, Debruyne F.
    Acta Otorhinolaryngol Belg; 1990 Oct 31; 44(4):415-21. PubMed ID: 2093285
    [Abstract] [Full Text] [Related]

  • 12. Ototoxicity of cisplatin in gynaecological cancer patients.
    Laurell G, Borg E.
    Scand Audiol; 1988 Oct 31; 17(4):241-7. PubMed ID: 3232027
    [Abstract] [Full Text] [Related]

  • 13. Carboplatin is ototoxic.
    Kennedy IC, Fitzharris BM, Colls BM, Atkinson CH.
    Cancer Chemother Pharmacol; 1990 Oct 31; 26(3):232-4. PubMed ID: 2192812
    [Abstract] [Full Text] [Related]

  • 14. High-frequency monitoring for early detection of cisplatin ototoxicity.
    Fausti SA, Henry JA, Schaffer HI, Olson DJ, Frey RH, Bagby GC.
    Arch Otolaryngol Head Neck Surg; 1993 Jun 31; 119(6):661-6. PubMed ID: 8499098
    [Abstract] [Full Text] [Related]

  • 15. Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with platin derivatives.
    Dhooge I, Dhooge C, Geukens S, De Clerck B, De Vel E, Vinck BM.
    Int J Audiol; 2006 Jun 31; 45(6):337-43. PubMed ID: 16777780
    [Abstract] [Full Text] [Related]

  • 16. The Relationship Between Cisplatin-related and Age-related Hearing Loss During an Extended Follow-up.
    Skalleberg J, Småstuen MC, Oldenburg J, Osnes T, Fosså SD, Bunne M.
    Laryngoscope; 2020 Sep 31; 130(9):E515-E521. PubMed ID: 32065408
    [Abstract] [Full Text] [Related]

  • 17. Extended high-frequency ototoxicity induced by the first administration of cisplatin.
    Sakamoto M, Kaga K, Kamio T.
    Otolaryngol Head Neck Surg; 2000 Jun 31; 122(6):828-33. PubMed ID: 10828794
    [Abstract] [Full Text] [Related]

  • 18. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
    Freilich RJ, Kraus DH, Budnick AS, Bayer LA, Finlay JL.
    Med Pediatr Oncol; 1996 Feb 31; 26(2):95-100. PubMed ID: 8531860
    [Abstract] [Full Text] [Related]

  • 19. Relationship between cisplatin administration and the development of ototoxicity.
    Rademaker-Lakhai JM, Crul M, Zuur L, Baas P, Beijnen JH, Simis YJ, van Zandwijk N, Schellens JH.
    J Clin Oncol; 2006 Feb 20; 24(6):918-24. PubMed ID: 16484702
    [Abstract] [Full Text] [Related]

  • 20. Audiological Monitoring in Children Treated with Platinum Chemotherapy.
    Fetoni AR, Ruggiero A, Lucidi D, De Corso E, Sergi B, Conti G, Paludetti G.
    Audiol Neurootol; 2016 Feb 20; 21(4):203-211. PubMed ID: 27286730
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.